Objective: To review drug interaction studies of glucagon-like ... needed to further assess and allow comparison of several GLP-1RA agents' impact on steady-state pharmacokinetics and ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

GLP-1 drugs, or GLP-1 receptor agonists, were originally solely intended for use as diabetes medications. However, they are now being used for a variety of purposes, including helping people with ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

Even as millions of older adults clamor for drugs such as Ozempic and Wegovy, monthly use of the medications known as GLP-1 receptor agonists soared nearly 600% between 2020 and 2023 in people under ...

Overall, average healthcare costs increased 46% over two years for patients trying GLP-1 drugs for obesity, from $12,695 to $18,507. The Congressional Budget Office states that there does not ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...